BRIEF-Akebia Therapeutics Provides Update On Vafseo For Non-Dialysis Patients

Reuters

Oct 29, 2025

BRIEF-Akebia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Provides Update On Vafseo For Non-Dialysis Patients

Oct 28 (Reuters) - Akebia Therapeutics Inc AKBA.O:

AKEBIA THERAPEUTICS PROVIDES UPDATE ON VAFSEO FOR NON-DIALYSIS PATIENTS
AKEBIA THERAPEUTICS INC - ANNOUNCES NO ALIGNMENT WITH FDA ON VALOR TRIAL DESIGN
AKEBIA THERAPEUTICS INC - WILL NOT INITIATE VALOR TRIAL OR PURSUE BROAD LABEL

Source text: ID:nGNXbnvY9y

Further company coverage: AKBA.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579997328"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579997328\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579997328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 04:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579997328","market":"nz","top_or_hot":-1,"title":"BRIEF-Akebia Therapeutics Provides Update On Vafseo For Non-Dialysis Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Update On Vafseo For Non-Dialysis Patients</title></head><body><p><span>Oct 28 (Reuters)</span><span> - </span>Akebia Therapeutics Inc <span>AKBA.O</span>:</p><ul><li><p>AKEBIA THERAPEUTICS PROVIDES UPDATE ON VAFSEO FOR NON-DIALYSIS PATIENTS</p></li><li><p>AKEBIA THERAPEUTICS INC - ANNOUNCES NO ALIGNMENT WITH FDA ON VALOR TRIAL DESIGN</p></li><li><p>AKEBIA THERAPEUTICS INC - WILL NOT INITIATE VALOR TRIAL OR PURSUE BROAD LABEL</p></li></ul><p>Source text: <span>ID:nGNXbnvY9y</span></p><p>Further company coverage: <span>AKBA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Akebia Therapeutics Provides Update On Vafseo For Non-Dialysis Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Akebia Therapeutics Provides Update On Vafseo For Non-Dialysis Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-29 04:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Provides Update On Vafseo For Non-Dialysis Patients</title></head><body><p><span>Oct 28 (Reuters)</span><span> - </span>Akebia Therapeutics Inc <span>AKBA.O</span>:</p><ul><li><p>AKEBIA THERAPEUTICS PROVIDES UPDATE ON VAFSEO FOR NON-DIALYSIS PATIENTS</p></li><li><p>AKEBIA THERAPEUTICS INC - ANNOUNCES NO ALIGNMENT WITH FDA ON VALOR TRIAL DESIGN</p></li><li><p>AKEBIA THERAPEUTICS INC - WILL NOT INITIATE VALOR TRIAL OR PURSUE BROAD LABEL</p></li></ul><p>Source text: <span>ID:nGNXbnvY9y</span></p><p>Further company coverage: <span>AKBA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA4Y0LXJ:1","article_id":"2579997328","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579997328","pubTimestamp":1761684878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Akebia Therapeutics Provides Update On Vafseo For Non-Dialysis PatientsOct 28 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS PROVIDES UPDATE ON VAFSEO FOR NON-DIALYSIS PATIENTSAK","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Akebia Therapeutics为非透析患者提供Vafseo的最新信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":0.9},"content_text":"BRIEF-Akebia Therapeutics Provides Update On Vafseo For Non-Dialysis PatientsOct 28 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS PROVIDES UPDATE ON VAFSEO FOR NON-DIALYSIS PATIENTSAKEBIA THERAPEUTICS INC - ANNOUNCES NO ALIGNMENT WITH FDA ON VALOR TRIAL DESIGNAKEBIA THERAPEUTICS INC - WILL NOT INITIATE VALOR TRIAL OR PURSUE BROAD LABELSource text: ID:nGNXbnvY9yFurther company coverage: AKBA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}